.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The quest for effective heart regeneration has faced significant challenges, particularly when translating pre-clinical laboratory success to aged human patients. Recent research on senotherapeutics in cardiac aging highlights that cellular senescence is a major barrier to successful therapy in patients older than 70 years. These dysfunctional cells create a hostile tissue microenvironment. Consequently, this environment prevents successful regeneration in the aging myocardium by inhibiting endogenous repair mechanisms.
The aged heart undergoes structural and functional changes driven by biological mechanisms like metabolic dysfunction and inflammaging. However, targeting senescent cells with senotherapeutics can effectively alleviate features like myocardial hypertrophy and fibrosis. Moreover, these drugs help clear the \"zombie cells\" that inhibit the heart's natural repair capacity. Consequently, these therapies rejuvenate the tissue microenvironment and activate endogenous regeneration. Therefore, they offer a promising adjunct to existing cardiac treatments.
Experimental medicine studies often rely on young animal models, which fail to reflect the reality of the actual patient population. Specifically, patients requiring regenerative treatments are usually elderly and possess a high senescent cell burden. Therefore, future myocardial therapies must undergo testing in pre-clinical models that strictly mimic the aged heart phenotype. Whether the approach is pharmacological, cell-based, or genetic, it requires a microenvironment conducive to repair. Furthermore, clinicians must prioritize models that accurately represent the biological complexity of aging patients to ensure clinical efficacy.
Senotherapeutics are pharmacological agents designed to target and either eliminate (senolytics) or modify (senomorphics) senescent cells to improve tissue function and health span.
Senescent cells secrete inflammatory factors known as the senescence-associated secretory phenotype (SASP). This creates a toxic environment that prevents cardiac stem cells and muscle tissue from repairing damage effectively.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Research highlights senotherapeutics as a key adjunct to rejuvenate the aged heart and enhance the efficacy of cardiac regenerative therapies in elderly pat...
5 months ago
As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today
A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
